Page results
-
Information about clinic-based after-care following treatment for childhood or teenage cancer at UCLH.
-
This information page aims to answer some of the questions you may have about receiving chimeric antigen receptor (CAR) T-cell therapy at University College London Hospitals NHS Foundation Trust (UCLH).
-
Events, classes and workshops at the Macmillan Support and Information Service (MSIS)
-
Latest news and developments in the Macmillan Support and Information Service
-
The UCLH immunotherapy-neurotoxicity multidisciplinary service (IO-neurotox MDT) was established collaboratively between the National Hospital for Neurology and Neurosurgery (NHNN) and a nationwide oncology clinical team to offer high-quality diagnostic and management guidance on the care of cancer patients with, or suspected of having, any form of neurological complication of immunotherapy (immune-checkpoint inhibitor therapy).
-
Information about staff who work in the Macmillan Support and Information Service.
-
The first UK trial to test the benefits of proton beam therapy for certain patients with breast cancer has launched at UCLH.
-
This is information for women who have been given a diagnosis of adenomyosis.
-
Our annual members' meeting (AMM) brings together members, governors and staff, and is where our governors officially receive our annual report and accounts.
-
Once again, UCLH has received the highest score of all general acute and acute/community NHS trusts in England for staff that would recommend us as a place to work
File results
-
FOI/2023/0214 - Patients waiting over 78 weeks for elective care
-
FOI/2023/0215 - British sign language procurement and communications
-
FOI/2023/0217 - Integration platform(s) at the Trust
-
FOI/2023/0218 - System for discharge letters, diagnostic reporting, digital dictation & bed management
-
FOI/2023/0220 - Internally produced patient information leaflets
-
FOI/2023/0222 - Contact details for senior screening and immunisations staff
-
FOI/2023/0224 - Patients prescribed medical equipment for use in the home
-
FOI/2023/0225 - Usage of Dabrafenib + Trametinib in cancer treatment
-
FOI/2023/0226 - Treatment with Nivolumab
-
FOI/2023/0227 - Number of radiographers and nuclear medicine clinical scientists at Trust